Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | CASP1 | P29466 | 3/20 | 0.61 |
| ▸ | CASP7 | P55210 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977465 | 1.00 | MAPT (0.61) | MAPTMEN1KMT2ATP53KDM4E | |
| SCHEMBL1421624 | 0.94 | MAPT (0.61) | MAPTMEN1KMT2ATP53KDM4E | |
| SCHEMBL1976922 | 0.93 | ABCB1 (0.60) | MAPTMEN1KMT2ATP53KDM4E | |
| SCHEMBL1974622 | 0.93 | ABCB1 (0.60) | MAPTMEN1KMT2ATP53KDM4E | |
| SCHEMBL1421455 | 0.86 | MAPT (0.58) | MAPTMEN1KMT2ATP53KDM4E | |
| SCHEMBL1421620 | 0.86 | MAPT (0.58) | MAPTMEN1KMT2ATP53KDM4E | |
| SCHEMBL1977319 | 0.84 | MEN1 (0.51) | MAPTMEN1KMT2ATP53KDM4E | |
| SCHEMBL1976331 | 0.84 | MEN1 (0.51) | MAPTMEN1KMT2ATP53KDM4E | |
| SCHEMBL1976811 | 0.81 | MEN1 (0.56) | MAPTMEN1KMT2ATP53KDM4E | |
| SCHEMBL1974544 | 0.81 | MEN1 (0.56) | MAPTMEN1KMT2ATP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | AXOGLIA THERAPEUTICS (LU) | 2011-06-16 | — | — | US | disclosed |
| EP-2112145-A1 | Chromenone derivatives useful for the treatment of neurodegenerative diseases | AxoGlia Therapeutics S.A. (LU) | 2009-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, CDR2, SNCA | MAPT 243/4885MEN1 1507/4885KMT2A 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.